A separate preclinical study also observed the enhanced antitumor immune response with significantly decreased FoxP3+ expression in circulating Tregs and increased tumor-infiltrating G-MDSCs in syngeneic mouse cancer models under entinostat and anti-PD-1 antibody treatment (Orillion et al., 2017). This evidence concerns the gene FOXP3 and neoplasm.